Antiviral ADC Program

About Thelper

Thelper AS is an Oslo-based biotech pioneering a novel approach to cancer therapy by targeting virally encoded proteins within solid tumors. Its platform focuses on developing antiviral antibody-drug conjugates (ADCs) designed for high tumor specificity and reduced toxicity. The company is in the preclinical stage, has secured seed funding and a research grant, and is led by a founder with strong clinical and industrial experience. Its strategy addresses a significant unmet need in aggressive, metastatic cancers with limited treatment options.

Therapeutic Areas